The Hyundai Cancer Institute at CHOC has added two oncologists, Dr. Josephine HaDuong and Dr. Ashley Plant-Fox, to its team of nationally recognized specialists. Both physicians were fellowship-trained at two of the country’s top cancer programs, and share research interest in immunotherapy and targeted therapies.
Dr. Josephine HaDuong
Board-certified in pediatric hematology and oncology, Dr. HaDuong was drawn to the Cancer Institute for what she refers to as its gold standard of care. “The Hyundai Cancer Institute is a growing center that strives to be among the best. The team provides patients access to cutting-edge clinical trials that may lead to breakthroughs in pediatric cancer,” says Dr. HaDuong.
A published author and principal investigator in a number of studies, Dr. HaDuong’s major research activities include exploring developmental therapeutics in solid tumors using immunomodulatory and targeted agents, as well as functional imaging in bone and soft tissue sarcomas using magnetic resonance spectroscopy. Her research is driven, in large part, by her clinical interest in caring for patients with solid tumors.
Following medical school at the University of Pittsburgh, where she earned a full tuition merit scholarship, Dr. HaDuong completed her residency and pediatric hematology/oncology fellowship training at Children’s Hospital Los Angeles. She was honored with the Fellow of the Year, Excellence in Teaching Award.
Dr. HaDuong is a member of numerous professional associations, including American Society of Clinical Oncology, American Society of Pediatric Hematology and Oncology, and North American Consortium for Histiocytosis. In addition to English, she speaks Spanish and Vietnamese.
Raised in Orange County, Dr. HaDuong is thrilled to be back in her hometown. “I have always wanted to return home to serve the children and families in Orange County. I look forward to being a part of an incredible team who works relentlessly to end cancer,” explains Dr. HaDuong.
Dr. Ashley Plant-Fox
Committed to growing CHOC’s neuro-oncology treatment program, Dr. Plant-Fox is eager to bring new and exciting therapies to patients with brain tumors. “I look forward to collaborating with academia and industry to bring early clinical trials to CHOC, especially in the area of immunotherapy. I am also excited to partner with my new colleagues to advance the work the Cancer Institute has been doing to reduce the long-term toxicities of cancer therapy,” says Dr. Plant-Fox.
A published author, Dr. Plant-Fox’s research interests include early-phase clinical trial design for pediatric brain tumors. Her most recent project is a phase 1 clinical trial for a neo-antigen heat shock protein vaccine for diffuse intrinsic pontine glioma, a fatal brain tumor. She hopes to enroll patients in this trial within the next year. She considers herself fortunate to have worked under world-renowned immuno-oncologists Dr. Glenn Dranoff and Dr. Jerome Ritz at Dana Farber Cancer Institute in Boston. There, she won the Young Investigator Award for a project evaluating clonality of T cell receptors in pediatric gliomas.
Following medical school at Stanford University, Dr. Plant-Fox finished her residency at University of California, Los Angeles. Her fellowship training in pediatric hematology/oncology was completed at Boston Children’s Hospital. She received additional training in clinical trials and public health at Harvard Chan School of Public Health.
“I was attracted to CHOC because the hospital prioritizes excellent clinical care of patients above all else,” says Dr. Plant-Fox. “The hospital’s commitment to patient-and-family-centered care is something I wholeheartedly support. Cancer affects everyone in the family – physically, emotionally, psychologically and sometimes even financially. If we fail to address these issues, we are not completely caring for our patients and their families.”
CHOC Hospital was named one of the nation’s best children’s hospitals by U.S. News & World Report in its 2022-23 Best Children’s Hospitals rankings and ranked in the cancer specialty.